.avif)
The landscape of medical weight loss is about to change again. Eli Lilly, the pharmaceutical company behind the highly successful Mounjaro (tirzepatide), has announced that its new once-daily oral medication — Orforglipron — could reach the UK as early as 2026, pending regulatory approval.
For millions of people who struggle with obesity but dislike the idea of weekly injections, this breakthrough could make treatment more accessible, convenient, and effective.
Orforglipron is part of a class of medicines called GLP-1 receptor agonists, a group already proven effective in medications such as Mounjaro, Wegovy, and Ozempic.
Unlike existing injectable versions, Orforglipron comes as a simple daily tablet. This could appeal to those who are needle-averse or prefer the practicality of oral medication while travelling.
The drug works by mimicking a natural hormone (GLP-1) that regulates appetite, digestion, and blood sugar. As a result, patients tend to feel fuller for longer, experience fewer cravings, and eat smaller portions without feeling deprived.
Eli Lilly has recently reported strong findings from its Phase 3 ATTAIN trials:
Crucially, results with Orforglipron were found to be comparable to Mounjaro injections — without the need for needles.
Eli Lilly is aiming to submit Orforglipron for regulatory approval in 2025. If approved, it could launch in the UK by 2026 — and the UK is expected to be one of the first countries to gain access.
Like other GLP-1 medications, it will likely be available privately first, with NHS rollout dependent on NICE guidance.
Pricing hasn’t yet been confirmed, but based on existing GLP-1 treatments, private prescriptions may cost between £100–£300 per month.
Orforglipron is expected to be prescribed for adults with:
Its oral format could particularly benefit those who:
As with all GLP-1 medications, the most common side effects are gastrointestinal and include:
These usually improve after the first few weeks as the body adjusts. Prescribers will typically use a titration schedule, starting with a lower dose and gradually increasing to minimise side effects.
Eli Lilly executives have suggested that Orforglipron could be a $100 billion global market by 2030. Beyond weight management, trials are already underway to explore its potential for obstructive sleep apnoea and high blood pressure in people with obesity.
Looking even further ahead, researchers are exploring the possibility of a “once-and-done” obesity treatment — a single injection that could permanently reset the body’s weight regulation.
Key Takeaway
The arrival of Orforglipron in 2026 could mark a turning point in weight-loss treatment. For the first time, patients may have access to a clinically effective, easy-to-take daily pill instead of injections — broadening access and reducing barriers to obesity care.
At Private Medical Clinic, we closely monitor these medical advances to offer our patients the most effective, evidence-based options.
If you’re interested in exploring current weight-loss treatments such as Mounjaro or Wegovy, or want to be kept informed about the arrival of Orforglipron, our experienced private GPs are here to help.
.png)
Dr. Simon Khela (MBChB, MRCGP) is Medical Director at Private Medical Clinic and an experienced Private GP with a special interest in Sport, Exercise, and Functional Medicine. He is passionate about preventative, personalised care and advancing healthcare through digital innovation and cutting-edge therapies.
